Transition Therapeutics to license to Eli Lilly
Biopharmaceutical company Transition Therapeutics Inc. (Nasdaq: TTHI) said it will license exclusive worldwide rights to pharmaceutical products juggernaut Eli Lilly and Co. (NYSE: LLY) to develop and commercialize Transition's gastrin based therapies. Shares climbed 14.3%, or $1.59, to $12.70 in pre-market trading.
For detailed price information and recent news stories about Transition Therapeutics, click TTHI.
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
